Reporter

With temperatures rising in Middle Tennessee, doctors at Monroe Carell Jr. Children’s Hospital at Vanderbilt stress the danger of leaving children unattended in vehicles.

A drug in use clinically to help make vaccines more effective may be a powerful new tool for fighting antibiotic-resistant infections.

After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverly Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.

Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis.

A five-year National Cancer Institute grant will fund an interdisciplinary research center for the study of small cell lung cancer, a highly aggressive, incurable form of the disease.

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.

Antimicrobial resistance continues to increase, and antimicrobial stewardship programs are developing plans to report antimicrobial use in order to reduce and optimize the use of antibiotics.